Revenue

Zacks Small Cap Research – LGMK: Potential Revenue Catalysts: GSA Approval, Medicaid Waivers, Device Upgrades – Go Health Pro

by
Zacks Small Cap Research – LGMK: Potential Revenue Catalysts: GSA Approval, Medicaid Waivers, Device Upgrades – Go Health Pro

By M. Marin NASDAQ:LGMK READ THE FULL LGMK RESEARCH REPORT Recent introduction of next-gen Guardian Alert 911 Plus in 1Q25… LogicMark, Inc. (NASDAQ:LGMK) launched the next generation of the Guardian Alert 911 Plus in February 2025. The next-generation Guardian Alert 911 Plus expands the company’s product suite and offers an upgrade from the earlier version … Read more

Zacks Small Cap Research – CTSO: CytoSorbents Reports 4th quarter and 2024 Financial Results Which Showed Impressive Product Revenue Growth That Exceeded Our Expectations. – Go Health Pro

by

By Thomas Kerr, CFA NASDAQ:CTSO READ THE FULL CTSO RESEARCH REPORT Update on the DrugSorb-ATR Regulatory Process Management reiterated that their De Novo DrugSorb-ATR submission continued to be in interactive review with FDA, that their Medical Device License application to Health Canada was in advanced review, and that they continue to expect regulatory decisions in … Read more

Zacks Small Cap Research – TSEM: Tower Expects Increasing Revenue in 2025 as Capacity Kicks In – Go Health Pro

by

By Lisa Thompson NASDAQ:TSEM READ THE FULL TSEM RESEARCH REPORT Tower (NASDAQ:TSEM) continued year-over-year revenue growth in Q4 2024 and expects that to continue sequentially and year-over-year throughout 2025. The growth will be back-half weighted as capacity comes online in Italy, Texas, and Japan. For the 2024 year, revenues and earnings were basically flat with … Read more

Zacks Small Cap Research – CTSO: CytoSorbents Reports Preliminary 4th Quarter and 2024 Financial Results Which Showed Impressive Product Revenue Growth That Exceeded Our Expectations. – Go Health Pro

by

By Thomas Kerr, CFA NASDAQ:CTSO READ THE FULL CTSO RESEARCH REPORT On January 3, 2025, CytoSorbents (NASDAQ:CTSO) reported strong preliminary 4th quarter and full year 2024 financial results which exceeded our expectations. 4th quarter product revenue (excluding grant income) is estimated to be in the range of $9.0-$9.2 million, which is approximately 22% to 25% … Read more

Zacks Small Cap Research – CLPMF: Clip Money Reports Q3 Revenue Growth of 250% – Go Health Pro

by

By Lisa Thompson OTC:CLPMF READ THE FULL CLPMF RESEARCH REPORT Revenue is ramping even faster than we expected, as shown by the Q3 earnings report. Revenue for Q3 2024 was $521,000 compared to $149,000 in Q3 of 2023, representing 250% growth. In the quarter, the number of new deposit users grew by 101%, and revenue … Read more